ANGPTL4 抗体 (AA 39-406)
Our Local Distributor
北京 101111
Quick Overview for ANGPTL4 抗体 (AA 39-406) (ABIN7874599)
抗原
See all ANGPTL4 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 39-406
-
原理
- ANGPTL4 Antibody / Angiopoietin-like 4
-
纯化方法
- Immunogen affinity purified
-
免疫原
- E.coli-derived human ANGPTL4 recombinant protein (Position: D39-S406) was used as the immunogen for the ANGPTL4 antibody.
-
亚型
- IgG
-
-
-
-
应用备注
- Optimal dilution of the ANGPTL4 antibody should be determined by the researcher.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL
-
缓冲液
- Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- After reconstitution, the ANGPTL4 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
-
-
- ANGPTL4 (Angiopoietin-Like 4 (ANGPTL4))
-
别名
- ANGPTL4
-
背景
-
ANGPTL4 antibody detects Angiopoietin-like 4, a secreted glycoprotein that plays critical roles in lipid metabolism, angiogenesis, wound healing, and tumor progression. Encoded by the ANGPTL4 gene on chromosome 19p13.3, the protein belongs to the angiopoietin-like family of vascular regulators, which share structural similarity to angiopoietins but act independently of the Tie receptor system. Angiopoietin-like 4 contains an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain that mediate distinct biological functions. The N-terminal region primarily regulates lipid metabolism, while the C-terminal fragment influences angiogenesis and vascular permeability.
Angiopoietin-like 4 is synthesized and secreted by adipose tissue, liver, skeletal muscle, and endothelial cells, where it modulates triglyceride homeostasis through inhibition of lipoprotein lipase (LPL). By preventing premature triglyceride hydrolysis, ANGPTL4 redistributes lipids among tissues during fasting and feeding cycles. This function has made ANGPTL4 a major focus of metabolic and cardiovascular research. Genetic studies demonstrate that loss-of-function variants in ANGPTL4 are associated with reduced plasma triglyceride levels and decreased risk of coronary artery disease, identifying it as a potential therapeutic target for dyslipidemia.
Beyond metabolism, Angiopoietin-like 4 exerts profound effects on vascular biology. It enhances endothelial barrier integrity in certain contexts while promoting permeability in others, depending on proteolytic processing and redox status. The C-terminal domain can stimulate endothelial cell migration and tube formation, processes crucial to wound healing and tumor angiogenesis. Elevated ANGPTL4 expression has been observed in hypoxic tumors, where it promotes metastasis by enhancing vascular leakiness and resistance to detachment-induced apoptosis (anoikis). Conversely, in some tissues, ANGPTL4 limits inflammation by preventing leukocyte extravasation and oxidative stress. These context-dependent effects highlight its dual regulatory capacity in physiology and disease.
The ANGPTL4 antibody is used in research focused on lipid metabolism, vascular biology, and cancer. In western blot assays, it detects both the full-length 50 kilodalton protein and its processed fragments. Immunohistochemistry demonstrates strong cytoplasmic and extracellular staining in adipocytes, endothelial cells, and hepatocytes. In cell culture studies, ANGPTL4 levels rise under hypoxic conditions or upon treatment with PPAR agonists, reflecting its transcriptional control by peroxisome proliferator-activated receptors. This antibody supports investigation into the pathways linking metabolism, angiogenesis, and inflammation.
Angiopoietin-like 4 also participates in tissue remodeling, wound repair, and fibrosis by regulating matrix metalloproteinase expression and fibroblast activity. Dysregulation contributes to pathologies such as diabetic retinopathy, where increased ANGPTL4 disrupts retinal vascular integrity. The ANGPTL4 antibody enables detection of these changes and facilitates translational research aimed at developing ANGPTL4-targeted therapies. NSJ Bioreagents provides this antibody validated for its applications, ensuring reliable detection across multiple species. -
UniProt
- Q9BY76
-
途径
- Regulation of Lipid Metabolism by PPARalpha
抗原
-